NIVF
NewGenIvf Group Limited
There isn't enough reported data to score NIVF yet.
NIVF Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
NIVF's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
NIVF PE Valuation
NIVF has no meaningful PE right now: it lost money over the past year.
NIVF Forward outlook
There aren't enough analyst estimates for NIVF to show an outlook.
NIVF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$11,059,200.00 | -456% |
| Q4 2023 | $3,110,400.00 | +23696% |
NIVF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $4.7M | -13% |
| Q4 2024 | $5.4M | +5.8% |
NIVF's revenue is growing: $5M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -227% | N/A |
| Q4 2024 | -21% | N/A |
| Q4 2023 | 0.8% | N/A |
NIVF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$11.1M | -$2.7M |
| Q4 2024 | -$8.3M | -$6.5M |
| Q4 2023 | -$1.8M | -$1.8M |
NIVF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | 0% | -- |
NIVF has 0 diluted shares, down 100% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
NIVF Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | 0.9x | Very low |
NIVF's net debt is less than a year of its operating earnings (EBITDA).
NIVF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.6 | Oversold |
| Stochastic | 0.0 | Oversold |
NIVF's weekly RSI is 26 (oversold) and its Stochastic is 0 (oversold).
NIVF PE vs Healthcare Sector
| Metric | NIVF | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NIVF has no meaningful PE right now: it lost money over the past year.
NIVF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.72 | 92% below |
| 20 week MA | $45.7 | 99% below |
| 50 week MA | $722.5 | 100% below |
| 100 week MA | $545,562.4 | 100% below |
| 200 week MA | $61,033,235.6 | 100% below |
NIVF is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NIVF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $169,862,400.0 | $176,083,200.0 | +3.7% |
| 2023 | $176,083,200.0 | $188,352,000.0 | +7% |
| 2024 | $188,352,000.0 | $7,395,840.0 | -96% |
| 2025 | $7,395,840.0 | $2,768.3 | -100% |
| 2026 YTD | $2,768.3 | $0.28 | -100% |
NIVF has finished lower in two of the last four years. It's down 100% so far in 2026.